Chronic Myelocytic Leukemia
(CML; Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia; Chronic Granulocytic Leukemia)
by Amy Scholten, MPH
Chronic myelogenous leukemia (CML) is a cancer of the blood and bone marrow. It is marked by changes in:
CML is often slow growing for many years. Over time, it may change into acute myelogenous leukemia (AML). AML is a faster and more serious type of leukemia.
In CML, the abnormal cells grow and crowd out other blood cells. This leads to problems with infections and bleeding.
CML is almost always linked to changes in a gene. The gene change may be caused by exposure to large amounts of radiation. However, in many people, the cause is not known.
CML is more common in older adults and men. Other things that may raise the risk are:
CML may cause:
The doctor will ask about your symptoms and health history. A physical exam will be done. The doctor will check for swelling of the liver, spleen, or lymph nodes.
Tests may include:
Testing confirms CML diagnosis.
For certain symptoms, imaging tests may be done to look at body structures. They may be:
CML is grouped into 3 phases. This helps the doctor know what to expect and what treatments to use.
The goal is to get rid of the cancer cells. Treatment depends on person's age, health, and phase of the CML. Options may be:
There are no guidelines to prevent CML.
American Cancer Society
The Leukemia and Lymphoma Society
Canadian Cancer Society
Provincial Health Services Authority
Breccia M, Efficace F. Are chronic myeloid leukemia patients ready to stop long-term treatment? Leuk Lymphoma. 2017;58(12):2976-2978.
Chronic myeloid leukemia (CML). American Cancer Society website. Available at: https://www.cancer.org/cancer/chronic-myeloid-leukemia.html. Accessed March 24,2021.
Chronic myeloid leukemia. EBSCO DynaMed website. Available at:https://www.dynamed.com/condition/chronic-myeloid-leukemia-cml . Accessed March 24, 2021.
General information about chronic myelogenous leukemia. National Cancer Institute website. Available at: https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq. Accessed March 24, 2021.
Last reviewed January 2021 by EBSCO Medical Review Board Mohei Abouzied, MD, FACP
Last Updated: 3/24/2021
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.